Filing Flows

Filing Flows › Companies › DarioHealth › Cash flow

DarioHealth cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$6.1M in Q2 2026 · −$25.5M over twelve months

Operating cash flow−$6.1M
Capital spending−$38K
Free cash flow−$6.1M

Analysis

In Q2 2026, DarioHealth generated −$6.1M of operating cash flow and spent $38K on capital projects, leaving free cash flow of −$6.1M. That is $46K less than in Q2 2025 (−$6.1M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$25.3M; the largest uses were operating cash flow ($25.3M), other investing ($7.2M), capital spending ($136K); the cash balance fell by $15.3M.

Operating cash flow was −$6.1M against net income of −$7.9M. The largest differences: stock-based pay +$632K, depreciation & amortization +$515K, inventory +$453K.

Free cash flow

DarioHealth: free cash flow by quarterDarioHealth: free cash flow by quarter−$7.4MQ3 2024−$6.8MQ4 2024−$6.7MQ1 2025−$6.1MQ2 2025−$7.4MQ3 2025−$5.9MQ4 2025−$6.1MQ1 2026−$6.1MQ2 2026
Operating cash flow less capital spending.
DarioHealth: operating cash flow against capital spendingDarioHealth: operating cash flow against capital spendingOperating cash flowCapital spending−$7.4M$32KQ3 2024−$6.7M$21KQ4 2024−$6.7M$31KQ1 2025−$6.0M$44KQ2 2025−$7.3M$41KQ3 2025−$5.9M$26KQ4 2025−$6.0M$31KQ1 2026−$6.1M$38KQ2 2026
Latest (Q2 2026): Operating cash flow −$6.1M, Capital spending $38K.

Capital allocation, year by year

DarioHealth: where the cash came from (up) and went (down), by fiscal yearDarioHealth: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow −$50.4MFY2021: Shares issued $65.1MFY2021: Capital spending −$261K$65.1MFY2021FY2022: Operating cash flow −$47.8MFY2022: Net borrowing $23.8MFY2022: Shares issued $38.3MFY2022: Capital spending −$442KFY2022: Buybacks −$134K$62.1MFY2022FY2023: Operating cash flow −$30.4MFY2023: Net borrowing $1.8MFY2023: Shares issued $14.9MFY2023: Capital spending −$584K$16.6MFY2023FY2024: Operating cash flow −$38.6MFY2024: Shares issued $38.5MFY2024: Capital spending −$138KFY2024: Acquisitions −$8.8M$38.5MFY2024FY2025: Operating cash flow −$25.9MFY2025: Net borrowing $185KFY2025: Shares issued $6.8MFY2025: Capital spending −$142K$6.9MFY2025
Over these 5 years operating cash flow totalled −$193M; the largest uses were operating cash flow ($193M) and acquisitions ($8.8M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$14.0M
Debt$31.1M
Net debt$17.1M
Cash runway7 months

DarioHealth is burning cash: its operations consume cash, a free cash flow of −$25.5M a year at the current rate against $14.0M of cash and investments: a runway of about 7 months before any new financing.

Where the cash came from and went

DarioHealth: sources (+) and uses (−) of cash, Q2 2026DarioHealth: sources (+) and uses (−) of cash, Q2 2026Cash drawn (+) / kept (−)$8.3MOperating cash flow−$6.1MOther investing−$2.2MCapital spending−$38KExchange rates$27KAsset & business sales$1K
DarioHealth: sources (+) and uses (−) of cash, TTM to Q2 2026DarioHealth: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$25.3MNot reconciled$17.4MCash drawn (+) / kept (−)$15.3MOther investing−$7.2MCapital spending−$136KExchange rates$31K

From profit to cash

DarioHealth: net income to operating cash flow, Q2 2026DarioHealth: net income to operating cash flow, Q2 2026Net income−$7.9MDepreciation & amortization$515KStock-based pay$632KOther non-cash−$35KInventory$453KPayables−$303KDeferred revenue$20KOperating cash flow−$6.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$6.1M−$38K—$8.3M−$6.1M
Q1 2026−$6.0M−$31K—$6.8M−$6.1M
Q4 2025−$5.9M−$26K—$10.1M−$5.9M
Q3 2025−$7.3M−$41K—−$10.0M−$7.4M
Q2 2025−$6.0M−$44K−$61K$5.9M−$6.1M
Q1 2025−$6.7M−$31K$6.8M−$90K−$6.7M
Q4 2024−$6.7M−$21K$18.3M−$11.6M−$6.8M
Q3 2024−$7.4M−$32K—$7.4M−$7.4M

DarioHealth: income statement and cash flow

DarioHealth, Q2 2026: revenue $5.2M (-4% year over year), operating margin -125.1%. The chart follows the revenue to costs, profit and cash.

DarioHealth: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.